Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to $7.0 million.

  • Palisade Bio's Liabilities and Shareholders Equity fell 2531.06% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.7 million, marking a year-over-year decrease of 3312.34%. This contributed to the annual value of $10.9 million for FY2024, which is 2257.33% down from last year.
  • Latest data reveals that Palisade Bio reported Liabilities and Shareholders Equity of $7.0 million as of Q3 2025, which was down 2531.06% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Palisade Bio's Liabilities and Shareholders Equity ranged from a high of $18.3 million in Q2 2023 and a low of $6.7 million during Q2 2025
  • Over the past 5 years, Palisade Bio's median Liabilities and Shareholders Equity value was $12.8 million (recorded in 2024), while the average stood at $12.3 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 13430.69% in 2023, then tumbled by 4820.14% in 2025.
  • Quarter analysis of 5 years shows Palisade Bio's Liabilities and Shareholders Equity stood at $16.3 million in 2021, then dropped by 3.14% to $15.8 million in 2022, then dropped by 10.85% to $14.1 million in 2023, then fell by 22.57% to $10.9 million in 2024, then crashed by 35.91% to $7.0 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $7.0 million for Q3 2025, versus $6.7 million for Q2 2025 and $8.2 million for Q1 2025.